Abstracts

Enhancing Anti-HIV Gene Therapy: Combining MegaTAL Nuclease Gene Editing With Selection Cassettes

Background: Human Immunodeficiency Virus (HIV) infection remains a substantial health problem worldwide. The human C-C chemokine receptor 5 (CCR5) gene, which encodes a co-receptor required for HIV entry into CD4+ T-cells, is a promising alternative therapeutic target. Early clinical trials using CCR5-disrupting zinc finger nucleases in patients have demonstrated sustained functional control of HIV during…

A Phase I Clinical Trial of Autologous CD4+ T Cells Modified With a Retroviral Vector Expressing the MazF Endoribonuclease in Patients With HIV-1

Background: The E.coli-derived MazF endoribonuclease specifically cleaves single stranded RNAs at ACA sequences. HIV-1 contains over 240 ACA sequences, making it especially sensitive to MazF activity. In this study, autologous CD4+ T cells are modified using a retroviral vector containing the mazF gene expressed under the control of the HIV LTR. MazF expression is thus…

CRISPRs Are Able to Efficiently Target Latent HIV and Halt New Infections

Background: Currently available combination antiretroviral therapy (cART) can successfully control HIV replication. However, conventional treatment lacks the ability to clear the latent reservoir and stop viral production, which remains the major obstacle in achieving a cure. Novel strategies are required to permanently disrupt the HIV genome in the latently infected cells. In this study we…

Histone Deacetylase (HDAC) and Histone Acetyltransferase (HAT) Inhibitors Have Opposing Effects on Cellular Susceptibility to HIV Infection

Background: Latency reversing agents (LRA), such as HDAC inhibitors, are being employed as part of a “shock-and-kill” approach to reactivate and eradicate latent proviruses. We recently reported that the HDAC inhibitor vorinostat significantly increases productive viral infection in vitro, raising potential concern for its use as a LRA in patients. This effect was also observed…

Panobinostat Dosing Has Broad but Transient Immunomodulatory Effects in HIV Patients

Background: To evaluate the immunomodulatory effects from HDACi in HIV-infected patients, we investigated a broad range of immune pathways during a latency reversal trial with panobinostat (PANO). Further, as prolonged epigenetic modulation from HDACi treatment has been raised as safety concern, we evaluated gene expression alterations up to 24 weeks after end of PANO dosing.…

Multi-Dose Romidepsin in SIV-Infected RMs Reactivates Latent Virus in Absence of ART

Background: Persistent viral reservoirs represent a major obstacle in eliminating HIV-1 in infected individuals, even with ART. One of the reservoir reactivation strategies is the “flush and kill” approach, in which latent virus is reactivated with histone deacetylase inhibitors (HDACi) and eliminated through effective CTL responses. Our goals were to: 1. develop a nonhuman primate…

Suberanilohydroxamic Acid (SAHA)-Induced Histone Modifications in the HIV Promoter in a Human, Primary CD4 T Cell Model of Latency

Background: Latently infected CD4 T cells are a major obstacle to HIV eradication with combined antiretroviral therapy (cART). Histone deacetylation at the HIV promoter leads to silencing of viral genes during latency. Use of histone deacetylase inhibitors (HDACi), in the presence of cART, to reactivate viral transcription has been proposed as a means to deplete…

Off-Target Effects of SAHA May Inhibit HIV Activation

Background: The latent HIV reservoir is the obstacle to a cure. HIV reactivation with histone deacetylase inhibitors (HDACis) such as SAHA (Vorinostat) in the presence of Highly Active Anti-Retroviral Therapy (HAART) is a candidate eradication strategy. However, the ability of SAHA to activate HIV in clinical trials appears limited. The primary action of SAHA thought…

Bystander Effect of Histone Deacetylase Inhibitors on HIV-1 Infection

Background: Histone deacetylase inhibitors (HDACi) are being evaluated in a “shock-and-kill” therapeutic approach to reverse HIV latency from CD4+ T cells. Although administered within the context of combination antiretroviral therapy (cART), infection of bystander cells remains a concern. In this study, we investigated the effect of HDACi on the replication kinetics of HIV within human…